Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Estring Clear all
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

NCT02860897
View directory record Official record
Conditions
Estrogen, Menopause, Pelvic Floor Disorders, Surgery
Interventions
Premarin, Vagifem
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 90 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 25, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

NCT05113368
View directory record Official record
Conditions
Ovarian Cancer, Serous Ovarian Cancer
Interventions
Regorafenib, Fulvestrant
Drug
Lead sponsor
Sarah K. Lynam MD
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 25, 2026, 5:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Withdrawn No phase listed Observational

Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

NCT00402935
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
14 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 25, 2026, 5:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine

NCT05738213
View directory record Official record
Conditions
Migraine
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) response, PedMIDAS (Pediatric Migraine Disability Assessment), Hormonal assessment, Pubertal status
Device · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
11 Years to 15 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

NCT02422615
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Ribociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Binge Eating & Birth Control

NCT04278755
View directory record Official record
Conditions
Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions
Drospirenone-Ethinyl Estradiol Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 25, 2026, 5:59 PM EDT
Recruiting Phase 3 Interventional

Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

NCT06969326
View directory record Official record
Conditions
Postoperative Bleeding, Gender Dysphoria, Hysterectomy
Interventions
Use of topical estradiol, No intervention
Drug · Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

NCT00903006
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, MK-0646, Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 25, 2026, 5:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

NCT04576455
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

NCT00141544
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

NCT00196352
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
11
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

NCT01109979
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Estradiol+MPA, Estradiol+Drospirenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 25, 2026, 5:59 PM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752
View directory record Official record
Conditions
Infertility
Interventions
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

NCT01178125
View directory record Official record
Conditions
Contraception, Female Contraception
Interventions
DR-102
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,858 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
52
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

NCT00932152
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Postmenopausal Women
Interventions
fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

Treatment of Prepubertal Labial Adhesions

NCT02218463
View directory record Official record
Conditions
Prepubertal Labial Adhesions
Interventions
Estradiol cream 0.01%, Cetaphil
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 12 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

NCT01381016
View directory record Official record
Conditions
Obesity, Infertility
Interventions
Estradiol, Gonadotropin-releasing hormone (GnRH), Progesterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 25, 2026, 5:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cyclic vs. Constant Estradiol: Regimens' Effects on Brain Health

NCT07831499
View directory record Official record
Conditions
Menopause, Healthy Adult, Brain, Postmenopausal
Interventions
Cyclic Estradiol, Continuous Estradiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
38 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 5:59 PM EDT